Tirzepatide was recently shown to reduce elevated fasting plasma glucagon in type 2 diabetes [21], but tirzepatide’s direct effect on alpha cells particularly in the context of type 1 diabetes remains unclear. Here, GCG is linked to type 1 diabetes mellitus.